<DOC>
	<DOC>NCT01511432</DOC>
	<brief_summary>The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.</brief_summary>
	<brief_title>A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<criteria>Healthy subjects (male and female of nonchildbearing potential) between the ages of 18 and 55 years Nonchildbearing potential female subjects Male subjects and female partners must agree to use at least 2 methods of contraception Subjects with a body mass index (BMI) of 18 to 30 kg/m2 and weigh &gt;50 kg at the Screening Visit. Subjects with a positive test result for hepatitis B, hepatitis C, or HIV Subjects with a significant history of any illness, as deemed important by the investigator or any condition possibly affecting drug absorption Subjects with a positive urine screen for drugs of abuse Subjects with a history of regular alcohol consumption Subjects treated with an investigational drug within 30 days For Part A only: Subjects with 12lead ECG QTcF &gt;450 msec (males) or QTcF &gt;470 msec (females) at the Screening Visit Subjects who use prescription and/or nonprescription medications or vitamins and/or dietary supplements Subjects who have made a blood donation of approximately 1 pint (500 mL) within 56 days prior to the first dose of study drug Subjects who have a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days of the last dose of study drug Subjects on hormone replacement therapy (HRT) must discontinue such therapy 28 days prior to the first dose of study drug Subjects who have a habit of using tobacco or nicotine containing products within 6 months before the Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Relative bioavailability</keyword>
	<keyword>telaprevir formulations</keyword>
</DOC>